News

Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one analysts forecast on, though the two are not defined identically. Analysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.

Companies with more cash than debt often have stronger financial flexibility, making them attractive in uncertain markets. With interest payments less of a worry, these businesses can invest more in growth, innovation, or buybacks and dividends.

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Intuitive Surgical (NasdaqGS:ISRG) received the world's first CE mark for transvaginal gynecologic procedures using its da Vinci SP system. The approval expands the da Vinci SP platform's labeled use in Europe to include transvaginal access for gynecologic surgery. The CE mark positions Intuitive Surgical as an early mover in single port, natural orifice gynecologic procedures in the region. The new CE mark for transvaginal gynecologic use is only one part of the broader Intuitive Surgical...

Intuitive Surgical's da Vinci meta-analysis across 14 million procedures found better perioperative outcomes versus laparoscopic and open surgery.

In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $377.94, denoting a +2.38% move from the preceding trading day.

Intuitive Surgical (ISRG) trades near $370, about 38% below its 52-week high, after growth in its US robotic-surgery procedures slowed. Selling a put pays you now for agreeing to buy the shares much lower, and you keep the payment either way. The catch is it only works if you would want this business at that price.

A major bank just dropped a forecast that reframes the entire robotics industry, and the ripple effects are already moving stock prices across chips, foundries, and factory floors. Here is what the number means for long-term investors.

Intuitive Surgical (NASDAQ:ISRG) executives said the company remains focused on global procedure growth, while acknowledging a recent deceleration in U.S. procedures and policy-related uncertainty affecting hospitals. Speaking at a Wells Fargo conference, Executive Vice President, CFO and Enterpris

Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.

Based on the average brokerage recommendation (ABR), Intuitive Surgical (ISRG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Medtronic has a historically high 3% yield and is just two years away from becoming a Dividend King.

Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $350.16, moving 4.51% from the previous trading session.

BOTZ offers diversified exposure to a robotics boom fueled by AI, humanoid robots and industrial automation, as the sector rapidly evolves.

Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.

Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.

In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.

The stock has dropped more than 30% this year.

Intuitive Surgical has notably underperformed the Health Care Equipment industry over the past year, but analysts are highly optimistic about the stock’s prospects.

Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.

In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $372.6, indicating a +1.51% shift from the previous trading day.

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

This is a market-broadening year for Intuitive Surgical. The company is expanding beyond its core da Vinci systems to serve a wider continuum of hospitals and surgery centers.

Intuitive Surgical (ISRG) has been back in focus after reporting another quarter of double digit revenue and procedure growth, supported by adoption of its da Vinci 5, single port system and Ion lung biopsy platform. Despite the strong quarterly update, Intuitive Surgical’s share price has been under pressure, with the stock down 34.09% on a year to date share price return and down 21.38% on a 1-year total shareholder return. This contrasts with its 16.27% total shareholder return over three...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% gain over the past six months, beating the S&P 500 by 13.3 percentage points.

ISRG's record cash flow is fueling R&D, manufacturing expansion and over 100 da Vinci 5 updates, strengthening its innovation edge.

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Its growth profile stands well above major sector peers.

While investors fixate on a slowdown in current procedures, hospitals are accelerating their investment in the company's core platform, revealing a crucial, under-appreciated strength.

Insider disposals, bearish options positioning, and fading retail sentiment are flashing caution on NVIDIA even as the fundamentals keep accelerating. Here is why our model reads that tension as an opportunity rather than a warning.